|Articles|February 24, 2021
ICON to Acquire PRA Health Sciences
Advertisement
ICON PLC has agreed to acquire PRA Health Sciences Inc. PRAH, 18.41% in a cash and stock deal valued at about $12 billion. Under the terms of the deal. Icon will pay $80 per share in cash plus 0.4125 shares of Icon stock for a roughly 30% premium over PRA's closing price Tuesday.
The deal is expected to close in the third quarter. The combined company will be headquartered in Dublin and continue to be led by CEO Steve Cutler, and CFO Brendan Brennan.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
2
Clarifying Ownership of IRT Data in Clinical Trials: Distinguishing Investigator-Controlled Data from Sponsor Operational Data
3
ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval
4
Building More Representative Cancer Trial Populations
5